Brain Shuttles: A New Path Into the Brain with James Gorman of the Wyss Institute

Matias interviews James (Jim) Gorman MD PhD from the Wyss Institute. Jim is Principal Investigator on the Wyss Institute Brain Targeting Program (BTP). Jim leads a team developing new approaches to transport drugs through the blood brain barrier (BBB) into the CNS.

In this episode, we discuss:

• Why the BBB blocks most modern drugs from entering the brain, creating the biggest bottleneck in neuro
• How brain shuttles hijack natural transport pathways like the transferrin receptor to move drugs across the BBB
• How new modalities that reach the brain can potentially treat diseases like Alzheimer’s, Parkinson’s, ALS, and lysosomal disorders
• Why delivery route of shuttles enable IV or subcutaneous dosing instead of invasive intrathecal injections
• How early data shows that shuttle-enabled antibodies clear amyloid faster, at lower doses, and with fewer side effects
• How the field is accelerating through a pre-competitive consortium model that lets multiple companies share shuttle platforms

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Caitlin Ner & Nico V. Rey

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank